Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH0G8W)

• Drug Name: KURARINONE Drug Info
• Synonyms: (-)-kurarinone; Kurarinone; CHEMBL243796; SCHEMBL10307523; BDBM50208612

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11982640
  ChEBI ID: CHEBI:66150
  CAS Number: CAS 34981-26-5
  TTD Drug ID: DMH0G8W
  VARIDT Drug ID: DR00951

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 1 (SGLT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[4]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[5]
YG1699	DM1NR1J	Type-1 diabetes	5A10	Phase 2	[6]
1614235 + 2330672	DMD751X	Type-2 diabetes	5A11	Phase 1	[5]
GSK1614235	DM7I1AQ	Type-2 diabetes	5A11	Phase 1	[7]
LX2761	DM8ZS7T	Type 2 diabetes	5A11	Phase 1	[8]
T-1095	DMGFS51	Diabetic complication	5A2Y	Discontinued in Phase 2	[9]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[10]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Beta-secretase (BACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(S)-FLURBIPROFEN	DMF2O4T	Myalgia	FB56.2	Preregistration	[11]
E-2609	DMTNUJ8	Alzheimer disease	8A20	Phase 3	[12]
verubecestat	DM4CGH5	Alzheimer disease	8A20	Phase 3	[13]
Lanabecestat	DMFJLB6	Alzheimer disease	8A20	Phase 3	[14]
AZD3293	DMJQHXD	Alzheimer disease	8A20	Phase 2/3	[15]
JNJ-54861911	DMGPJ5U	Alzheimer disease	8A20	Phase 2/3	[14]
R-flurbiprofen	DMFIVSR	N. A.	N. A.	Phase 2	[11]
LY2886721	DMV14LM	Alzheimer disease	8A20	Phase 2	[16]
LY3202626	DM7IFNB	Alzheimer disease	8A20	Phase 2	[14]
AZD-3839	DM72FOD	Alzheimer disease	8A20	Phase 1	[17]

Drug(s) Targeting SLC5A2 messenger RNA (SLC5A2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexagliflozin	DMK56G0	Type 2 diabetes	5A11	Approved	[18]
ISIS-SGLT2	DMDKAIC	Type-2 diabetes	5A11	Phase 1	[19]
KURAIDIN	DMLDUJ1	Discovery agent	N.A.	Investigative	[1]
10-methoxy-N(1)-methylburnamine-17-O-veratrate	DMJW25X	Discovery agent	N.A.	Investigative	[10]
Alstiphyllanine F	DMKRAEW	Discovery agent	N.A.	Investigative	[10]
Kushenol N	DMY13UR	Discovery agent	N.A.	Investigative	[1]
Alstiphyllanine E	DMTNQ5E	Discovery agent	N.A.	Investigative	[10]
Burnamine-17-O-3',4',5'-trimethoxybenzoate	DMBO0WI	Discovery agent	N.A.	Investigative	[10]
Alstiphyllanine D	DM2FLDJ	Discovery agent	N.A.	Investigative	[10]
O-spiroketal glucoside	DM3FS62	Discovery agent	N.A.	Investigative	[20]

Drug(s) Affected By Chimeric ERCC6-PGBD3 protein (ERCC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[23]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[24]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[25]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[24]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[26]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[27]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-secretase (BACE)	TT8JRS7	NOUNIPROTAC	Inhibitor	[2]
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[1]
Sodium/glucose cotransporter 1 (SGLT1)	TT2UE56	SC5A1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Chimeric ERCC6-PGBD3 protein (ERCC6)	OT2QZKSF	ERPG3_HUMAN	Drug Response	[3]
DNA repair protein complementing XP-C cells	OTB09PXO	XPC_HUMAN	Drug Response	[3]

References

• [1] Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9.
• [2] BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74.
• [3] The endoperoxide ascaridol shows strong differential cytotoxicity in nucleotide excision repair-deficient cells. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):302-10. doi: 10.1016/j.taap.2012.01.006. Epub 2012 Jan 17.
• [4] LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915).
• [6] ClinicalTrials.gov (NCT04956263) A Comparison of Postprandial Glucose After a Mixed Meal Tolerance Test, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study of the Dual Systemic SGLT1 and SGLT2 Inhibitor YG1699, and the Selective SGLT2 Inhibitor Dapagliflozin in Subjects With Type 1 Diabetes. U.S.National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [8] Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals.
• [9] T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800.
• [10] Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158.
• [11] The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
• [12] Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329.
• [13] BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008.
• [16] Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9.
• [17] Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [20] ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32.
• [21] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [22] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells. Cancer Lett. 2012 Mar;316(1):62-9. doi: 10.1016/j.canlet.2011.10.022. Epub 2011 Oct 23.
• [25] Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol. 2011 Mar 21;24(3):340-9. doi: 10.1021/tx1003112. Epub 2011 Jan 14.
• [26] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [27] Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13487-92. doi: 10.1073/pnas.1414135111. Epub 2014 Aug 18.
• [28] Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. J Biol Chem. 2011 Apr 15;286(15):12991-3001. doi: 10.1074/jbc.M110.190645. Epub 2011 Feb 15.